The new network will reach nearly 40 million patients in the US. Credit: CDC on Unsplash.

Veradigm and PRA Health Sciences have partnered to establish an electronic healthcare record (EHR)-based clinical research network in the US.

The new network will reach around 25,000 physicians and 40 million patients across the country.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It leverages Veradigm’s StudySource platform, which boosts current EHR systems to comprise clinical research, along with PRA’s eSource technology and clinical research capabilities.

Physicians can use the network to provide clinical research as a care option (CRACCO) to their patients. This approach could improve clinical trials’ process efficacies, accessibility and diversity.

Veradigm Life Sciences Research business vice-president and general manager Stephanie Reisinger said: “Under this agreement, the Veradigm and PRA-led network aims to transform the clinical research processes by extending EHR workflows to include clinical research as well as fully leveraging the rich data from digital healthcare delivery.

“The scale of Veradigm’s EHR footprint with PRA’s eSource technology and deep trial expertise will enable us to literally bring studies to where the patients are.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Data management and tracking are considered long and expensive steps of a trial but most of this information is already available in EHR systems, Veradigm noted.

PRA Health’s eSource technology can automatically transfer data from Veradigm’s EHRs to an electronic data capture system, in turn expediting drug development via reduced time and effort in this step.

The automated process could also decrease transcription errors and enhance data quality while mitigating the expensive verification of source data.

PRA Health Sciences executive vice-president and chief scientific officer Kent Thoelke said: “We are evolving and modernising the drug development paradigm by integrating it with everyday healthcare delivery.”

In February this year, Irish company ICON entered an agreement to acquire PRA Health Sciences in a cash and stock deal valued at about $12bn.